Nigericin sodium salt

Nigericin sodium salt 是从吸水链霉菌中得到的一种抗生素，作为 H⁺，K⁺ 和 Pb²⁺ 离子载体起作用。

Nigericin sodium salt产品描述：Nigericin sodium salt is an antibiotic from Streptomyces hygroscopicus that works by acting as an H⁺, K⁺, and Pb²⁺ ionophore.

In Vitro:Nigericin (0.1 µM) decreases inhibits proliferation and clonogenicity of
H460 lung cancer cells in a dose dependent manner. Nigericin inhibits
migration and invasion of H460 lung cancer cells^[1].
Nigericin (0.1-10 nM) has apparently a dual effect on cell volume, that
is a shrinking effect at lower Nigericin concentrations and a swelling
effect at higher concentrations. Nigericin (0.1-1 nM) significantly
decreases cytosolic pH (pHi), and slightly increases the pHi at 5 and 10
nM^[2]. Nigericin exhibits higher toxicity on S18 cells than S26 cells, with IC₅₀ of 2.03±0.55 μM and 4.77±2.35 μM, respectively. Nigericin can
selectively kill cancer stem cells in NPC in vitro. Nigericin
dramatically reduces the migration ability of S18 and HONE-1 cells^[3]. Nigericin exhibits gteat toxicity for the HT29 and SW116 cell line with IC₅₀ of 12.92±0.25 μmol and 15.86±0.18 μmol. Nigericin also shows a
decreased ability to form colonies under anchorage-independent
conditions in a standard soft agar assay^[4].

In Vivo: Milrinone (1 μg/kg/min, i.v.) significantly
reduces PAP, PVR (?18.96 ± 1.7%), and LAP (?26.03 ± 2.3%) in congestive
heart failure (CHF) rats. Milrinone (1 mg/mL, inhalation) results in a
near-maximal reduction of PAP without significant effects on AP,
decreases pulmonary artery pressure similarly in a larger collective of
CHF rats. Milrinone Ngericin (4 mg/kg, i.p.) significantly reduces tumor growth and acts
synergistically with the chemotherapeutic agent DDP, as shown by the
tumor volumes. Nigericin markedly decreases Bmi-1 in vivo.
Overexpression of Bmi-1 partially restores CSC content and metastatic
ability of NPC cells under Nigericin treatment. The downregulation of
Bmi-1 may be involved in the inhibitory effect of Nigericin on CSCs in
NPC^[3].





公司介绍：MedChemExpress(MCE)专注于各种YZ剂、激动剂、API及化合物库，总部位于美国新泽西，分别在瑞典和上海设有欧洲区子公司和亚洲区总代理，营销网点遍及20多个国家地区。MCE经过多年努力已成为生物活性小分子领域的供应商，
产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域，PI3K、MAPK等近千个细分靶点，超过4000个活性小分子化合物现货，以及GPCR、API、离子通道等超过20种不同类型的化合物库，同时提供从毫克到千克的专业定制合成服务。

MCE 对每批产品都进行严格的LCMS和NMR检验，其产品已被近万名客户广泛使用并发表大量文章、；

MCE 定期增加各领域热门YZ剂、激动剂，不断扩增已有化合物库，以满足新的科研需求；

数千种产品在上海有充足备货，24-48小时内送达客户；

大量产品提供免费SY装； 已为多个知名企业、院校构建各种定制型化合物库。



Purity:98%

MWt:746.9432

Formula:C40H67NaO11

SMILES:C[C@H]1[C@](O[C@@H]2C[C@](CC[C@@H]3C)([H])O[C@@]3([H])[C@@H](C)C([O-])=O)([C@@H]([C@H](OC)C2)C)O[C@](C)([C@]4([H])O[C@](C)([C@]5([H])O[C@]([C@@]([C@H](C[C@H]6C)C)([H])O[C@@]6(O)CO)([H])C[C@@H]5C)CC4)C1.[Na+]

Pathway:Membrane Transporter/Ion Channel;

Mechanisms:Potassium Channel;

Research Area:Cancer